High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: A literature-based meta-analysis

Annals of Oncology

Volumn 21, Issue 5, 2009, Pages 1064-1071

  Azim, H A ^a,d   Santoro, L ^b   Bociek, R G ^c   Gandini, S ^b   Malek, R A ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d CAIRO UNIVERSITY   (Egypt)

Author keywords

Chemotherapy; CHOP; Dose intensity; Doxorubicin; Non Hodgkin's lymphoma

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; HUMAN; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 77952242297     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp425     Document Type: Article

References (28)

1. Armitage JO, Bierman PJ, Bociek RG, Vose J. Lymphoma 2006: classification and treatment. Oncology 2006; 20: 231-239.
2. Naresh KN, Advani S, Adde M et al. Report of an International Network of Cancer Treatment and Research workshop on non-Hodgkin's lymphoma in developing countries. Blood Cells Mol Dis 2004; 33: 330-337.
3. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared to CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
4. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
5. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963-977.
6. Gams RA, Rainey M, Dandy M et al. Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial. J Clin Oncol 1985; 3: 1188-1195.
7. Takagi T, Sampi K, Sawada U et al. A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: a prospective randomized study. Int J Hematol 1993; 57: 67-71.
8. Osby E, Hagberg H, Kvaloy S et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003; 101: 3840-3848.
9. Fisher RI, Gaynor ER, Dahlberg S et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate-or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 1994; 5: S91-S95.
10. Wolf M, Mathews JP, Stone J et al. Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Ann Oncol 1997; 8: S71-S75.
11. Jerkeman M, Anderson H, Cavallin-Stahl E et al. CHOP versus MACOP-B in aggressive lymphoma-a Nordic lymphoma group randomized trial. Ann Oncol 1999; 10: 1079-1086.
12. Linch DC, Smith P, Hancock BW et al. A randomized British national lymphoma investigation trial of CHOP vs. a weekly multiagent regimen (PACEBOM) in atients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol 2000; 11: S87-S90.
13. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-633.
14. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
15. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin's lymphoma. Blood 2003; 102: 4284-4289.
16. Verdonck LF, Notenboom A, de Jong DD et al. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 2007; 109: 2759-2766.
17. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
18. Cooper IA, Wolf MM, Robertson TI et al. Randomised comparison of MACOP-B with CHOP in patients with intermediate-grade Non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 769-778.
19. Linch DC, Vaughan Hudson B, Hancock BW et al. A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report. Br J Cancer 1996; 74: 318-322.
20. Greenland S. Quantitative methods in the review of epidemiology literature. Epidemiol Rev 1987; 9: 1-30.
21. Woolf B. On estimating the relation between blood groups and disease. Ann Hum Genet 1955; 19: 251-253.
22. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
23. Higgings JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
24. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001; 20: 641-654.
25. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
26. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group (erratum appears in J Clin Oncol 2000;18:2351). J Clin Oncol 1999; 17: 1244-1253.
27. Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
28. Clarke MJ, Stewart LA. Obtaining individual patient data from randomized controlled trials. In Egger M, Smith GD, Altmnan DG (eds): Systemic Reviews in Health Care. London, UK: BMJ Publishing Group 2001; 109-121.